Implications of Endodontic-related Sinus Aspergillosis in a Patient Treated by Infliximab: A Case Report

Guivarc’h, Maud; Ordioni, Ugo; Catherine, Jean-Hugues; Campana, Fabrice; Camps, Jean; Bukiet, Frédéric

doi:10.1016/j.joen.2014.09.022

Cited by 11 publications

(14 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, three case reports, in contrast with the other studies, highlighted that the presence of an oral disease concomitant with the administration of BMs might be associated with infective complications from untreated AP or from inadequate root canal treatment (i.e. overfilling in the maxillary sinus) . Based on the review, the answer to question 1 (a) is that the use of BMs in the presence of AP or P is most frequently associated with amelioration of the periodontal conditions, but in individual cases of untreated, or inadequately treated, oral infections it might increase the chances of infective complications.…”

Section: Resultsmentioning

confidence: 99%

“…Quality of information in the In vivo animal studies was considered moderate in five articles and high in seven studies . The assessment of the case reports classified one article as a low quality; two articles as moderate, and four articles as high‐quality of information . Considering the high to moderate overall quality of the studies and the scarcity of studies investigating this topic, all the studies meeting the inclusion criteria were included in the present review to provide the best and most comprehensive evidence available.…”

Section: Resultsmentioning

confidence: 99%

“…The answer to the first review question is that BMs therapy appears to be associated with a positive outcome on a pre‐existing inflammation of the periodontal tissues, yet this conclusion seems to be overshadowed by the chance of increased infective complications as reported in few cases …”

Section: Discussionmentioning

confidence: 99%

“…In a second case the patient was heavily compromized and had also been under alendronate therapy; whereas in another report the dental history of the patient was not clearly assessed . Finally, two more reports described the insurgence of infective complications following inadequate dental treatments in patients under BMs . In one of them, endodontic treatment complicated by the extrusion of root canal sealer in the maxillary sinus promoted the development of an aspergillosis .…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Interaction of biologic therapy with apical periodontitis and periodontitis: a systematic review

Peddis

Musu

Ideo

et al. 2019

Australian Dental Journal

View full text Add to dashboard Cite

Biologic medications (BMs) are increasingly used for the management of systemic chronic inflammatory diseases. These diseases are often associated with a higher prevalence of apical periodontitis (AP) and periodontitis (P). The purpose of this systematic review was to ascertain the interactions between AP and/or P and BMs. The review was registered in the PROSPERO database (CRD42017054756). Electronic searches were performed on Pubmed Medline, Scopus and The Web of Science from their inception through to 20 March 2018. The references of the articles selected were checked. The keywords were chosen based on a pilot search, which aimed to find the most frequently prescribed BMs. The included studies were appraised qualitatively using appropriate tools. Thirty-five articles met the inclusion criteria, comprising 16 non-randomized clinical studies, 12 in vivo animal studies and 7 case reports. Quality of information was assessed as high in 18 articles, moderate in 16 articles and low in 1 article. BMs in patients suffering from chronic inflammatory diseases seems to inhibit the progression of AP and P, and to enhance the healing response to periodontal and endodontic treatment. A healthier condition of the periodontal tissues seems to be associated with a better response of the patient to BMs therapy.Abbreviations and acronyms: AP = apical periodontitis; BM = biologic medications; P = periodontitis; RANKL = receptor activator of nuclear factor kappa-Β ligand (RANKL).

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Interaction of biologic therapy with apical periodontitis and periodontitis: a systematic review

Peddis

Musu

Ideo

et al. 2019

Australian Dental Journal

View full text Add to dashboard Cite

show abstract

“…Adalimumab, a recombinant human immunoglobulin G monoclonal antibody, binds the TNF-a and prevents its interaction with the cell-surface TNF receptors (43). All biologic drugs could increase the risk of infection or set the ground for the reactivation of previous infections; the interferences of biologics on the treatment of chronic dental diseases like AP is still not completely known (43,46).…”

Section: Discussionmentioning

confidence: 99%

A Case of SAPHO Syndrome with Endodontic Implications and Treatment with Biologic Drugs

Cotti

Careddu

Schirru

et al. 2015

Journal of Endodontics

View full text Add to dashboard Cite

COVID-19-associated opportunistic infections: a snapshot on the current reports

2021

View full text Add to dashboard Cite

Treatment of the novel Coronavirus Disease 2019 (COVID-19) remains a complicated challenge, especially among patients with severe disease. In recent studies, immunosuppressive therapy has shown promising results for control of the cytokine storm syndrome (CSS) in severe cases of COVID-19. However, it is well documented that immunosuppressive agents ( e.g., corticosteroids and cytokine blockers) increase the risk of opportunistic infections. On the other hand, several opportunistic infections were reported in COVID-19 patients, including Aspergillus spp . , Candida spp . , Cryptococcus neoformans , Pneumocystis jiroveci ( carinii ), mucormycosis, Cytomegalovirus (CMV), Herpes simplex virus (HSV), Strongyloides stercoralis, Mycobacterium tuberculosis, and Toxoplasma gondii . This review is a snapshot about the main opportunistic infections that reported among COVID-19 patients. As such, we summarized information about the main immunosuppressive agents that were used in recent clinical trials for COVID-19 patients and the risk of opportunistic infections following these treatments. We also discussed about the main challenges regarding diagnosis and treatment of COVID-19-associated opportunistic infections (CAOIs). Supplementary Information The online version contains supplementary material available at 10.1007/s10238-021-00751-7.

show abstract

Implications of Endodontic-related Sinus Aspergillosis in a Patient Treated by Infliximab: A Case Report

Cited by 11 publications

References 40 publications

Interaction of biologic therapy with apical periodontitis and periodontitis: a systematic review

Interaction of biologic therapy with apical periodontitis and periodontitis: a systematic review

A Case of SAPHO Syndrome with Endodontic Implications and Treatment with Biologic Drugs

COVID-19-associated opportunistic infections: a snapshot on the current reports

Contact Info

Product

Resources

About